AR098740A1 - Análogos del péptido exendina-4 - Google Patents
Análogos del péptido exendina-4Info
- Publication number
- AR098740A1 AR098740A1 ARP140104639A ARP140104639A AR098740A1 AR 098740 A1 AR098740 A1 AR 098740A1 AR P140104639 A ARP140104639 A AR P140104639A AR P140104639 A ARP140104639 A AR P140104639A AR 098740 A1 AR098740 A1 AR 098740A1
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- amino acid
- acid residue
- residue selected
- gln
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a derivados de exendina-4 y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, que incluyen diabetes y obesidad, además de reducción de la ingesta excesiva de alimentos. Reivindicación 1: Un compuesto peptídico que tiene la fórmula (1): R¹-Z-R² (1) en donde Z es un resto de péptido que tiene la fórmula (2): His-X²-X³-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Leu-Asp-Glu-Gln-X¹⁸-Ala-X²⁰-X²¹-Phe-Ile-Glu-Trp-Leu-Ile-X²⁸-Gly-Gly-Pro-X³²-Ser-Gly-AIa-Pro-Pro-Pro-Ser (2) X² representa un residuo de aminoácido seleccionado de Ser, D-Ser y Aib, X³ representa un residuo de aminoácido seleccionado de Gln y His, X¹⁸ representa un residuo de aminoácido seleccionado de Leu y His X²⁰ representa un residuo de aminoácido seleccionado de His, Arg, Lys, (S)MeLys y Gln, X²¹ representa un residuo de aminoácido seleccionado de Asp y Glu, X²⁸ representa un residuo de aminoácido seleccionado de Lys, Ser y Ala, X³² representa un residuo de aminoácido seleccionado de Ser y Val, R¹ representa NH₂, R² representa OH o NH₂, o una sal o solvato del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306716 | 2013-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098740A1 true AR098740A1 (es) | 2016-06-08 |
Family
ID=49883000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104639A AR098740A1 (es) | 2013-12-13 | 2014-12-12 | Análogos del péptido exendina-4 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150166625A1 (es) |
EP (1) | EP3080151A1 (es) |
AR (1) | AR098740A1 (es) |
TW (1) | TW201609798A (es) |
WO (1) | WO2015086732A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
US11123405B2 (en) | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
AR110299A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
US11541028B2 (en) * | 2018-01-03 | 2023-01-03 | Altimmune Inc. | Peptide pharmaceuticals for treatment of NASH and other disorders |
JP7434169B2 (ja) | 2018-04-10 | 2024-02-20 | サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 固相からの固相結合ペプチドの切断方法 |
JP7332620B2 (ja) | 2018-04-10 | 2023-08-23 | サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | キャップ付加を伴うリキシセナチドの合成 |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1891105E (pt) * | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
EA200870575A1 (ru) * | 2006-05-26 | 2009-08-28 | Амилин Фармасьютикалз, Инк. | Композиции и способы лечения застойной сердечной недостаточности |
EP2300035B1 (en) * | 2008-06-17 | 2015-08-12 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
CL2009001424A1 (es) * | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
-
2014
- 2014-12-11 TW TW103143202A patent/TW201609798A/zh unknown
- 2014-12-11 EP EP14830953.7A patent/EP3080151A1/en not_active Withdrawn
- 2014-12-11 WO PCT/EP2014/077340 patent/WO2015086732A1/en active Application Filing
- 2014-12-12 US US14/569,373 patent/US20150166625A1/en not_active Abandoned
- 2014-12-12 AR ARP140104639A patent/AR098740A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201609798A (zh) | 2016-03-16 |
WO2015086732A1 (en) | 2015-06-18 |
EP3080151A1 (en) | 2016-10-19 |
US20150166625A1 (en) | 2015-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098740A1 (es) | Análogos del péptido exendina-4 | |
AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
AR110300A1 (es) | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip | |
AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
PH12019500517A1 (en) | Long-acting formulations of insulins | |
AR091866A1 (es) | Analogos del glucagon | |
AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
PE20151808A1 (es) | Peptidos terapeuticos | |
BR112014023374A2 (pt) | composições de peptídeos de glp-1 e preparação das mesmas | |
UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
PE20200606A1 (es) | Composiciones solidas para administracion oral | |
AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
UY38067A (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
AR105269A1 (es) | Péptidos y derivados de péptidos de colecistoquinina (cck) y sus usos | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
BR112015017909A2 (pt) | redução do risco de doença autoimune | |
CL2016001472A1 (es) | Nuevo compuesto análogo del glucagón constituido por una secuencia aminoacídica asociada con un ácido alfa aminobutírico, formulación farmacéutica que la comprende y su uso para el tratamiento de hipoglicemia severa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |